Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第8页

Acceptability and willingness to pay for a hypothetical HIV vaccine in Brazil and the implications: a cross-sectional study. 巴西对假定的艾滋病疫苗的接受度和支付意愿及其影响：一项横断面研究。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-07-24 DOI: 10.1080/14737167.2024.2384543

Vinícius Gonçalves Nogueira, Edna Afonso Reis, Brian Godman, Antony Paul Martin, Isabella Piassi Dias Godói

{"title":"Acceptability and willingness to pay for a hypothetical HIV vaccine in Brazil and the implications: a cross-sectional study.","authors":"Vinícius Gonçalves Nogueira, Edna Afonso Reis, Brian Godman, Antony Paul Martin, Isabella Piassi Dias Godói","doi":"10.1080/14737167.2024.2384543","DOIUrl":"https://doi.org/10.1080/14737167.2024.2384543","url":null,"abstract":"Introduction: The Human Immunodeficiency Virus (HIV) is one of the greatest public health challenges still facing communities worldwide, and until this moment, no vaccine is available for its prevention. In Brazil, the Rio de Janeiro State has stood out regarding the prevalence of this disease. As a result, an important state to consider the Willingness to Pay (WTP) for a hypothetical HIV vaccine to help with future pricing.Methods: A cross-sectional study was conducted to assess the acceptability and WTP of individuals from Rio de Janeiro State for a hypothetical HIV vaccine with a 70% efficacy.Results: 600 individuals were interviewed and the acceptability for this hypothetical vaccine was 77.2%. In addition, 452 participants were eligible for the WTP analysis and would accept a WTP US$79.37 (400 BRL) for this vaccine, a higher value than that found in another study (200 BRL) conducted in the Northern region of Brazil under the same methodological conditions.Conclusion: Economic studies such as WTP can contribute to discussions regarding the prices and specifications for future vaccines, particularly for a HIV vaccine in countries such as Brazil with over 5,000 municipalities spread across regions with diverse characteristics and challenges in terms of socioeconomic, epidemiological and cultural differences.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Barriers to digital endpoints in data collection in low and middle-income countries. 中低收入国家在数据收集方面面临的数字终端障碍。

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-07-01 Epub Date: 2024-03-18 DOI: 10.1080/14737167.2024.2331047

Ahmad Z Al Meslamani

引用次数: 0

Leveraging sensor-based functional outcomes to enhance understanding of the patient experience: challenges and opportunities. 利用基于传感器的功能性结果加强对患者体验的了解：挑战与机遇。

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-07-01 Epub Date: 2024-06-11 DOI: 10.1080/14737167.2024.2362291

Katelyn R Keyloun, Jessica Abel, Julia K Garcia, Elektra J Papadopoulos, Robyn T Carson, Chad Gwaltney, Ashley F Slagle, Bill Byrom

{"title":"Leveraging sensor-based functional outcomes to enhance understanding of the patient experience: challenges and opportunities.","authors":"Katelyn R Keyloun, Jessica Abel, Julia K Garcia, Elektra J Papadopoulos, Robyn T Carson, Chad Gwaltney, Ashley F Slagle, Bill Byrom","doi":"10.1080/14737167.2024.2362291","DOIUrl":"10.1080/14737167.2024.2362291","url":null,"abstract":"Introduction: Sensor-based digital health technology (DHT) has emerged as a promising means to assess patient functioning within and outside clinical trials. Sensor-based functional outcomes (SBFOs) provide valuable insights that complement other measures of how a patient feels or functions to enhance understanding of the patient experience to inform medical product development.Areas covered: This perspective paper provides recommendations for defining SBFOs, discusses the core evidence required to support SBFOs to inform decision-making, and considers future directions for the field.Expert commentary: The clinical outcome assessment (COA) development process provides an important starting point for developing patient-centered SBFOs; however, given the infancy of the field, SBFO development may benefit from a hybrid approach to evidence generation by merging exploratory data analysis with patient engagement in measure development. Effective SBFO development requires combining unique expertise in patient engagement, measurement and regulatory science, and digital health and analytics. Challenges specific to SBFO development include identifying concepts of interest, ensuring measurement of meaningful aspects of health, and identifying thresholds for meaningful change. SBFOs are complementary to other COAs and, as part of an integrated evidence strategy, offer great promise in fostering a holistic understanding of patient experience and treatment benefits, particularly in real-world settings.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of data processing algorithm to calculate adherence for adults with cystic fibrosis using inhaled therapy - a multi-center observational study within the CFHealthHub learning health system. 开发数据处理算法，计算使用吸入疗法的成年囊性纤维化患者的依从性--CFHealthHub 学习健康系统内的一项多中心观察研究。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-07-01 Epub Date: 2024-03-12 DOI: 10.1080/14737167.2024.2328085

Robert D Sandler, Lana Lai, Sophie Dawson, Sarah Cameron, Aoife Lynam, Matthew Sperrin, Zhe Hui Hoo, Martin J Wildman

{"title":"Development of data processing algorithm to calculate adherence for adults with cystic fibrosis using inhaled therapy - a multi-center observational study within the CFHealthHub learning health system.","authors":"Robert D Sandler, Lana Lai, Sophie Dawson, Sarah Cameron, Aoife Lynam, Matthew Sperrin, Zhe Hui Hoo, Martin J Wildman","doi":"10.1080/14737167.2024.2328085","DOIUrl":"10.1080/14737167.2024.2328085","url":null,"abstract":"Objectives: To develop a robust algorithm to accurately calculate 'daily complete dose counts' for inhaled medicines, used in percent adherence calculations, from electronically-captured nebulizer data within the CFHealthHub Learning Health System.Methods: A multi-center, cross-sectional study involved participants and clinicians reviewing real-world inhaled medicine usage records and triangulating them with objective nebulizer data to establish a consensus on 'daily complete dose counts.' An algorithm, which used only objective nebulizer data, was then developed using a derivation dataset and evaluated using internal validation dataset. The agreement and accuracy between the algorithm-derived and consensus-derived 'daily complete dose counts' was examined, with the consensus-derived count as the reference standard.Results: Twelve people with CF participated. The algorithm derived a 'daily complete dose count' by screening out 'invalid' doses (those <60s in duration or run in cleaning mode), combining all doses starting within 120s of each other, and then screening out all doses with duration < 480s which were interrupted by power supply failure. The kappa co-efficient was 0.85 (0.71-0.91) in the derivation and 0.86 (0.77-0.94) in the validation dataset.Conclusions: The algorithm demonstrated strong agreement with the participant-clinician consensus, enhancing confidence in CFHealthHub data. Publishingdata processing methods can encourage trust in digital endpoints and serve as an exemplar for other projects.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the full potential of digital endpoints for decision making: a novel modular evidence concept enabling re-use and advancing collaboration. 释放数字终点在决策制定中的全部潜力：一种新颖的模块化证据概念，可实现重复使用并促进合作。

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-07-01 Epub Date: 2024-05-15 DOI: 10.1080/14737167.2024.2334347

Lada Leyens, John Batchelor, Erwin De Beuckelaer, Kai Langel, Bert Hartog

{"title":"Unlocking the full potential of digital endpoints for decision making: a novel modular evidence concept enabling re-use and advancing collaboration.","authors":"Lada Leyens, John Batchelor, Erwin De Beuckelaer, Kai Langel, Bert Hartog","doi":"10.1080/14737167.2024.2334347","DOIUrl":"10.1080/14737167.2024.2334347","url":null,"abstract":"Introduction: Over the last decade increasing examples indicate opportunities to measure patient functioning and its relevance for clinical and regulatory decision making via endpoints collected through digital health technologies. More recently, we have seen such measures support primary study endpoints and enable smaller trials. The field is advancing fast: validation requirements have been proposed in the literature and regulators are releasing new guidances to review these endpoints. Pharmaceutical companies are embracing collaborations to develop them and working with academia and patient organizations in their development. However, the road to validation and regulatory acceptance is lengthy. The full value of digital endpoints cannot be unlocked until better collaboration and modular evidence frameworks are developed enabling re-use of evidence and repurposing of digital endpoints.Areas covered: This paper proposes a solution by presenting a novel modular evidence framework -the Digital Evidence Ecosystem and Protocols (DEEP)- enabling repurposing of measurement solutions, re-use of evidence, application of standards and also facilitates collaboration with health technology assessment bodies.Expert opinion: The integration of digital endpoints in healthcare, essential for personalized and remote care, requires harmonization and transparency. The proposed novel stack model offers a modular approach, fostering collaboration and expediting the adoption in patient care.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve. 高血压试验中医生和患者的依从性：一个有待解决的重要问题的观点。

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-07-01 Epub Date: 2024-06-05 DOI: 10.1080/14737167.2024.2363401

Michel Burnier

{"title":"Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve.","authors":"Michel Burnier","doi":"10.1080/14737167.2024.2363401","DOIUrl":"10.1080/14737167.2024.2363401","url":null,"abstract":"Introduction: Randomized controlled trials (RCTs) are important sources of evidence that strongly influence guidelines for patient management, including for elevated blood pressure in adults.Areas covered: Critical questions regarding the interpretation of hypertension trial results have recently increased, especially for concerns over methodology. In particular, investigator adherence to the protocol and patient adherence to investigational drugs are often far from optimal. These issues may be ignored or underreported because physicians' behavior during trials is often not monitored and patients' medication adherence is neither measured adequately nor reported or analyzed in the final report or in the publication. This situation may lead to misinterpretations of study results and misevaluations of the safety and efficacy profile of new drugs. In this short review, the problem of measuring, reporting, and analyzing drug adherence in RCTs is discussed and illustrated with several examples in the field of hypertension.Expert opinion: The main conclusion is that drug adherence should always be measured in clinical trials, possibly with more than one method. In addition, prespecified analyses of adherence data should be included in the statistical plan of all trials to improve their overall quality.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141247685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Digital measures in epilepsy in low-resourced environments. 低资源环境下癫痫的数字测量。

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-07-01 Epub Date: 2023-10-20 DOI: 10.1080/14737167.2023.2270163

Amza Ali, Dave F Clarke

{"title":"Digital measures in epilepsy in low-resourced environments.","authors":"Amza Ali, Dave F Clarke","doi":"10.1080/14737167.2023.2270163","DOIUrl":"10.1080/14737167.2023.2270163","url":null,"abstract":"Introduction: Digital measures and digital health-care delivery have been rarely implemented in lower-and-middle-income countries (LMICs), contributing to worsening global disparities and inequities. Sustainable ways to implement and use digital approaches will help to improve time to access, management, and quality of life in persons with epilepsy, goals that remain unreachable in under-resourced communities. As under-resourced environments differ in human and economic resources, no one approach will be appropriate to all LMICs.Areas covered: Digital health and tools to monitor and measure digital endpoints and metrics of quality of life will need to be developed or adapted to the specific needs of under-resourced areas. Portable technologies may partially address the urban-rural divide. Careful delineation of stakeholders and their engagement and alignment in all efforts is critically important if these initiatives are to be successfully sustained. Privacy issues, neglected in many regions globally, must be purposefully addressed.Expert opinion: Epilepsy care in under-resourced environments has been limited by the lack of relevant technologies for diagnosis and treatment. Digital biomarkers, and investigative technological advances, may finally make it feasible to sustainably improve care delivery and ultimately quality of life including personalized epilepsy care.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41196041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The long-term clinical impact of digital endpoints and biomarkers in data collection. 数据收集中的数字终点和生物标记的长期临床影响。

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-07-01 Epub Date: 2024-02-19 DOI: 10.1080/14737167.2024.2320233

Ahmad Z Al Meslamani

引用次数: 0

The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients. 心脏设备网络安全责任的影响以及政策制定者、制造商和患者面临的挑战。

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-07-01 Epub Date: 2024-05-29 DOI: 10.1080/14737167.2024.2361076

Bhakti Patel, Amgad N Makaryus

{"title":"The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients.","authors":"Bhakti Patel, Amgad N Makaryus","doi":"10.1080/14737167.2024.2361076","DOIUrl":"10.1080/14737167.2024.2361076","url":null,"abstract":"Introduction: As digital health expands, reliance on digital endpoints is rapidly increasing to improve diagnostic accuracy and management in the healthcare field. Digital endpoints are beneficial to monitor how patient's clinical information is processed outside of a clinical setting.Areas covered: Implications of cardiac digital endpoints play a role in allowing patients to track their clinical data outside of a clinical setting. Advances in cardiac digital endpoints involve advanced devices and implants, trackers, and artificial intelligence. We will explore further digital endpoints within cardiology and threats as well as security concerns for policies to focus on the maintenance of safe patient health data analysis, transmission, and processing.Expert opinion: As digital endpoints evolve and expand, policymakers must ensure there is adequate cybersecurity surrounding them. We believe guidelines should be in place to make sure data is accessed solely on a secure connection and access to digital literacy for patients should be readily available.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141160000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Video-based assessments of activities of daily living: generating real-world evidence in pediatric rare diseases. 基于视频的日常生活活动评估：为儿科罕见病提供真实证据。

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-07-01 Epub Date: 2024-06-07 DOI: 10.1080/14737167.2024.2360201

Elisa Ferrer-Mallol, Clare Matthews, Rabia Aziza, Alejandro Mendoza, Navdeep Sahota, Sandra Komarzynski, Rashmi Lakshminarayana, Elin Haf Davies

{"title":"Video-based assessments of activities of daily living: generating real-world evidence in pediatric rare diseases.","authors":"Elisa Ferrer-Mallol, Clare Matthews, Rabia Aziza, Alejandro Mendoza, Navdeep Sahota, Sandra Komarzynski, Rashmi Lakshminarayana, Elin Haf Davies","doi":"10.1080/14737167.2024.2360201","DOIUrl":"10.1080/14737167.2024.2360201","url":null,"abstract":"Introduction: Preserving function and independence to perform activities of daily living (ADL) is critical for patients and carers to manage the burden of care and improve quality of life. In children living with rare diseases, video recording ADLs offer the opportunity to collect the patients' experience in a real-life setting and accurately reflect treatment effectiveness on outcomes that matter to patients and families.Areas covered: We reviewed the measurement of ADL in pediatric rare diseases and the use of video to develop at-home electronic clinical outcome assessments (eCOA) by leveraging smartphone apps and artificial intelligence-based analysis. We broadly searched PubMed using Boolean combinations of the following MeSH terms 'Rare Diseases,' 'Quality of Life,' 'Activities of Daily Living,' 'Child,' 'Video Recording,' 'Outcome Assessment, Healthcare,' 'Intellectual disability,' and 'Genetic Diseases, Inborn.' Non-controlled vocabulary was used to include human pose estimation in movement analysis.Expert opinion: Broad uptake of video eCOA in drug development is linked to the generation of technical and clinical validation evidence to confidently assess a patient's functional abilities. Software platforms handling video data must align with quality regulations to ensure data integrity, security, and privacy. Regulatory flexibility and optimized validation processes should facilitate video eCOA to support benefit/risk drug assessment.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141093280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0